Alternative administration routes and delivery technologies for polio vaccines

References

• Polio Eradication & Endgame Strategic Plan 2013-2018. (Ed.) (Global Polio Eradication Initiative. 2013. Available from: http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_A4.pdf
   Google Scholar
• Okayasu H, Sutter RW, Jafari HS, et al. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(Suppl 1):S459S464.
   Google Scholar
• Warren J, Ziherl FA, Kish AW, et al. Large-scale administration of vaccines by means of an automatic jet injection syringe. J Am Med Assoc. 1955;157(8):633–637.
   PubMed Web of Science ®Google Scholar
• Lipson MJ, Carver DH, Eleff MG, et al. Antibody response to poliomyelitis vaccine administered by jet injection. Am J Public Health Nations Health. 1958;48(5):599–603.
   PubMed Web of Science ®Google Scholar
• Kelly K, Loskutov A, Zehrung D, et al. Preventing contamination between injections with multiple-use nozzle needle-free injectors: a safety trial. Vaccine. 2008;26(10):1344–1352.
   PubMed Web of Science ®Google Scholar
• Hoffman PN, Abuknesha RA, Andrews NJ, et al. A model to assess the infection potential of jet injectors used in mass immunisation. Vaccine. 2001;19(2829):4020–4027.
   PubMed Web of Science ®Google Scholar
• Soonawala D, Verdijk P, Wijmenga-Monsuur AJ, et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine. 2013;31(36):3688–3694.
   PubMed Web of Science ®Google Scholar
• Kraan H, Ploemen I, Van De Wijdeven G, et al. Alternative delivery of a thermostable inactivated polio vaccine. Vaccine. 2015;33(17):2030–2037.
   PubMed Web of Science ®Google Scholar
• Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–3208.
   PubMed Web of Science ®Google Scholar
• Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines. 2008;7(8):1201–1214.
   PubMed Web of Science ®Google Scholar
• Amorij JP, Kersten GF, Saluja V, et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release. 2012;161(2):363–376.
   PubMed Web of Science ®Google Scholar
• Hickling JK, Jones KR, Friede M, et al. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ. 2011;89(3):221–226.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andreasen LV, Andersen P, et al. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. Plos One. 2014;9(6):e100879.
   PubMed Web of Science ®Google Scholar
• Norton EB, Bauer DL, Weldon WC, et al. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33(16):1909–1915.
   PubMed Web of Science ®Google Scholar
• Van der Maaden K, Trietsch SJ, Kraan H, et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm Res. 2014;31(7):1846–1854.
   PubMed Web of Science ®Google Scholar
• Kouiavskaia D, Mirochnitchenko O, Dragunsky E, et al. Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study. J Infect Dis. 2015;211(9):1447–1450.
   PubMed Web of Science ®Google Scholar
• Edens C, Dybdahl-Sissoko NC, Weldon WC, et al. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine. 2015;33(37):4712–4718.
   PubMed Web of Science ®Google Scholar
• Van der Maaden K, Sekerdag E, Schipper P, et al. Layer-by-layer assembly of inactivated poliovirus and N-Trimethyl chitosan on pH-sensitive microneedles for dermal vaccination. Langmuir. 2015;31(31):8654–8660.
   PubMed Web of Science ®Google Scholar
• White JA, Blum JS, Hosken NA, et al. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum Vaccin Immunother. 2014;10(12):3611–3621.
   PubMed Web of Science ®Google Scholar
• Nirmal S, Cherian T, Samuel BU, et al. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine. 1998;16(910):928–931.
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362(25):2351–2359.
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201(9):1344–1352.
   PubMed Web of Science ®Google Scholar
• Estivariz CF, Jafari H, Sutter RW, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis. 2012;12(2):128–135.
   PubMed Web of Science ®Google Scholar
• Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012;16(2):e110e116.
   Web of Science ®Google Scholar
• Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368(5):416–424.
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Mach O, et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine. 2015;33(2):307–313.
   PubMed Web of Science ®Google Scholar
• Anand A, Zaman K, Estivariz CF, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine. 2015;33(48):6816–6822.
   PubMed Web of Science ®Google Scholar
• Salk JE. Recent studies on immunization against poliomyelitis. Pediatrics. 1953;12(5):471–482.
   PubMed Web of Science ®Google Scholar
• Connolly JH, Dick GW. Antibody response following intradermal or oral administration of formalinised poliomyelitis. Lancet. 1958;2(7042):333–336.
   PubMed Web of Science ®Google Scholar
• Sigurdsson B, Gudnadottir M, Petursson G. Response to poliomyelitis vaccination. Lancet. 1958;1(7016):370–371.
   PubMed Web of Science ®Google Scholar
• Von Magnus H. Salk: control of polio with non-infectious vaccine. New York: NY Acadamy of Sciences; 1957.
   Google Scholar
• Von Magnus H, Von Magnus P, Petersen I, et al. Polio vaccination in Denmark in April-June 1955. I. The production of formalinized poliovaccine and preliminary results. Dan Med Bull. 1955;2(8):226–233.
   PubMedGoogle Scholar
• Nelson KS, Janssen JM, Troy SB, et al. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine. 2012;30(2):121–125.
   PubMed Web of Science ®Google Scholar
• Van Wezel AL, Van Steenis G, Hannik CA, et al. [Preparation and use of inactivated vaccine against acute anterior poliomyelitis in the Netherlands]. Ned Tijdschr Geneeskd. 1979;123(12):466–474.
   PubMedGoogle Scholar
• Samuel BU, Cherian T, Sridharan G, et al. Immune response to intradermally injected inactivated poliovirus vaccine. Lancet. 1991;338(8763):343–344.
   PubMed Web of Science ®Google Scholar
• Samuel BU, Cherian T, Rajasingh J, et al. Immune response of infants to inactivated poliovirus vaccine injected intradermally. Vaccine. 1992;10(2):135.
   PubMed Web of Science ®Google Scholar
• WHO. Eliminating needles. the Polio Pipeline. 2008;1:2.
   Google Scholar
• Sutter RW, Pallansch MA, Sawyer LA, et al. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci. 1995;754:289–299.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Thorley M, Yamamura Y, et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis. 2007;195(1):12–20.
   PubMed Web of Science ®Google Scholar
• Sormunen H, Stenvik M, Eskola J, et al. Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine. J Med Virol. 2001;63(4):305–310.
   PubMed Web of Science ®Google Scholar
• WHO. Improving IPV. the Polio Pipeline. 2008;1:2–3.
   Google Scholar
• Bal SM, Caussin J, Pavel S, et al. In vivo assessment of safety of microneedle arrays in human skin. Eur J Pharm Sci. 2008;35(3):193–202.
   PubMed Web of Science ®Google Scholar
• Van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. J Control Release. 2012;161(2):645–655.
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Holmgren J. Vaccines against enteric infections for the developing world. Philos Trans R Soc Lond B Biol Sci. 2015;370(1671):142.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Svennerholm A-M. Vaccines against mucosal infections. Curr Opin Immunol. 2012;24(3):343–353.
   PubMed Web of Science ®Google Scholar
• Cong Y, Bowdon HR, Elson CO. Identification of an immunodominant T cell epitope on cholera toxin. Eur J Immunol. 1996;26(11):2587–2594.
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng. 2012;14:17–46.
   PubMed Web of Science ®Google Scholar
• Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis. 1984;6(Suppl 2):S361S368.
   Google Scholar
• Ogra PL, Karzon DT, Righthand F, et al. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N Engl J Med. 1968;279(17):893–900.
   PubMed Web of Science ®Google Scholar
• Krugman RD, Hardy GE Jr., Sellers C, et al. Antibody persistence after primary immunization with trivalent oral poliovirus vaccine. Pediatrics. 1977;60(1):80–82.
   PubMed Web of Science ®Google Scholar
• Trivello R, Renzulli G, Farisano G, et al. Persistence of poliovirus-neutralizing antibodies 2-16 years after immunization with live attenuated vaccine. A seroepidemiologic survey in the mainland of Venice. Epidemiol Infect. 1988;101(3):605–609.
   PubMed Web of Science ®Google Scholar
• Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599.
   PubMed Web of Science ®Google Scholar
• Patel M, Zipursky S, Orenstein W, et al. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14(5):749–762.
   PubMed Web of Science ®Google Scholar
• Sutter RW, John TJ, Jain H, et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376(9753):1682–1688.
   PubMed Web of Science ®Google Scholar
• Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec. 2010;85(23):213–228.
   PubMedGoogle Scholar
• el-Sayed N, El-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med. 2008;359(16):1655–1665.
   PubMed Web of Science ®Google Scholar
• Jenkins HE, Aylward RB, Gasasira A, et al. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med. 2008;359(16):1666–1674.
   PubMed Web of Science ®Google Scholar
• Waggie Z, Geldenhuys H, Sutter RW, et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis. 2012;205(2):228–236.
   PubMed Web of Science ®Google Scholar
• Vignuzzi M, Stone JK, Arnold JJ, et al. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 2006;439(7074):344–348.
   PubMed Web of Science ®Google Scholar
• Macadam AJ, Ferguson G, Stone DM, et al. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication. J Virol. 2006;80(17):8653–8663.
   PubMed Web of Science ®Google Scholar
• Burns CC, Shaw J, Campagnoli R, et al. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region. J Virol. 2006;80(7):3259–3272.
   PubMed Web of Science ®Google Scholar
• Kraan H, Vrieling H, Czerkinsky C, et al. Buccal and sublingual vaccine delivery. J Control Release. 2014;190:580–592.
   PubMed Web of Science ®Google Scholar
• Stratton LP, Dong A, Manning MC, et al. Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel. J Pharm Sci. 1997;86(9):1006–1010.
   PubMed Web of Science ®Google Scholar
• Coeshott CM, Smithson SL, Verderber E, et al. Pluronic F127-based systemic vaccine delivery systems. Vaccine. 2004;22(19):2396–2405.
   PubMed Web of Science ®Google Scholar
• Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery–a promising option for orally less efficient drugs. J Control Release. 2006;114(1):15–40.
   PubMed Web of Science ®Google Scholar
• Kiyono H, Fukuyama S. NALT- versus Peyer’s-patch-mediated mucosal immunity. Nat Rev Immunol. 2004;4(9):699–710.
   PubMed Web of Science ®Google Scholar
• Cochi SL, Linkins RW. The final phase of polio eradication: new vaccines and complex choices. J Infect Dis. 2012;205(2):169–171.
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med. 2004;350(9):896–903.
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol. 2012;354:1–18.
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Anjuere F, McGhee JR, et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev. 1999;170:197–222.
   PubMed Web of Science ®Google Scholar
• Chen D, Endres R, Maa YF, et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine. 2003;21(2122):2830–2836.
   PubMed Web of Science ®Google Scholar
• Chen D, Endres RL, Erickson CA, et al. Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. Vaccine. 2002;20(2122):2671–2679.
   PubMed Web of Science ®Google Scholar
• Maa YF, Shu C, Ameri M, et al. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm Res. 2003;20(7):969–977.
   PubMed Web of Science ®Google Scholar
• Skountzou I, Quan F-S, Jacob J, et al. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine. 2006;24(3536):6110–6119.
   PubMed Web of Science ®Google Scholar
• Jafari H, Deshpande JM, Sutter RW, et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science. 2014;345(6199):922–925.
   PubMed Web of Science ®Google Scholar
• John J, Giri S, Karthikeyan AS, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet. 2014;384(9953):1505–1512.
   PubMed Web of Science ®Google Scholar
• Saletti G, Cuburu N, Yang JS, et al. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc. 2013;8(6):1073–1087.
   PubMed Web of Science ®Google Scholar
• Global Vaccine Action Plan, Secretariat Annual Report 2014. (Ed.^(Eds) WHO. 2014. Available from: http://www.who.int/immunization/global_vaccine_action_plan/gvap_secretariat_report_2014.pdf?ua=1X
   Google Scholar